Home World News FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing... World News FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1378 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Benefit Assessment of Adding Irinotecan to Capecitabine-Based Neoadjuvant Chemoradiation for Locally... November 3, 2020 No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer... September 9, 2021 Young Women with Breast Cancer Often Forgo Hormone Therapy Due to... May 1, 2021 Darolutamide in Combination with ADT and Docetaxel Increases Overall Survival in... February 27, 2023 Load more HOT NEWS Cancer Survivors Face High Rates of Housing Insecurity 24-Year-Old Woman with Terminal Breast Cancer Dreams of Fairytale Wedding with... FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma... Avapritinib Not Superior to Regorafenib in Terms of Median PFS in...